GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:19 2024-05-17 am EDT			5-day change	1st Jan Change
1,775 ^GBX	-0.48%		-1.36%	+22.40%

May. 17	UK's FTSE 100 Closes Lower Amid Inflation Focus	MT
May. 17	Marti Technologies Hires Oguz Erkan as CFO	MT

BioVersys AG announced that it has received CHF 44.9 million in funding from AMR Action Fund GP, LLC, GSK plc and other investor.

May 06, 2024

On May 7, 2024, BioVersys AG closed the transaction. The company issued common shares for CHF 12.3 million in its third and final tranche, bringing a total funding of CHF 44.9 million in the transaction. The transaction included participation from new investor GSK plc.

Latest news about GSK plc

UK's FTSE 100 Closes Lower Amid Inflation Focus	May. 17	MT
Marti Technologies Hires Oguz Erkan as CFO	May. 17	MT
GSK Sells Remaining Stake in Haleon for $1.58 Billion	May. 17	MT
FTSE 100 slides; Eurozone inflation steady	May. 17	AN
London stocks dip as global rates outlook weighs	May. 17	RE
GSK: sale of remaining stake in Haleon	May. 17	CF
GSK sells remaining Haleon stake for GBP1.25 billion	May. 17	AN
FTSE 100 lacklustre as Wall Street rally ends	May. 17	AN
London stocks lacklustre but set for weekly gains	May. 17	RE
Land Securities ups dividend; GSK sells Haleon stake	May. 17	AN
GSK Divests Remaining Haleon Stake in GBP1.25 Billion Deal	May. 17	MT
GSK Sells Last Haleon Shares for $1.58 Billion	May. 17	DJ
GSK raises $1.5 bln from sale of remaining Haleon stake	May. 17	RE
GSK Raises About 1.25 Bln Stg Via Haleon Stake Sale	May. 17	RE
GSK: FOLLOWING SETTLEMENT OF PLACING, GSK WILL HAVE FULLY EXITED…	May. 17	RE
GSK: AGREED TO SELL 385,320,110 ORDINARY SHARES IN HALEON AT A P…	May. 17	RE
GSK to Sell Remaining Haleon Stake	May. 16	MT
GSK to Sell Remaining Stake in Haleon Valued at Around $1.27 Billion -- Update	May. 16	DJ
GSK intends to sell its remaining stake in Haleon	May. 16	RE
GSK to Sell Stake in Haleon Valued at About $1.61 Billion	May. 16	DJ
GSK to sell remaining holding in spin-off Haleon	May. 16	AN
GSK Plans to Sell 385 Million Haleon Shares	May. 16	MT
GSK Plans to Sell About 385 Million Haleon Shares, Bloomberg Reports	May. 16	MT
GSK intends to sell its entire stake in Haleon	May. 16	RE
Europe struggles but record highs in New York	May. 16	AN

Chart GSK plc

Duration

Period

More charts

Company Profile

GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.

Sector

Pharmaceuticals

Calendar

2024-05-19 - Barclays European Select Conference

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

GSK plc : Back on track

May 03, 2024 at 05:17 am EDT

GSK PLC : Encouraging start to 2024; guidance raised

May 01, 2024 at 11:38 am EDT

More Strategies

Ratings for GSK plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

17.75 GBP

Average target price

20.32 GBP

Spread / Average Target

+14.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GSK PLC	+22.40%	91.97B
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B

Other Pharmaceuticals

GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

BioVersys AG announced that it has received CHF 44.9 million in funding from AMR Action Fund GP, LLC, GSK plc and other investor.

EPS Revisions